相关实验视频

Updated: Jul 16, 2025

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

达帕格利弗洛辛对心室再极化在心力衰竭患者减少喷射分数的心脏衰竭的作用

Masaaki Nakase¹, Kazuyuki Yahagi², Yu Horiuchi¹

¹Division of Cardiology, Mitsui Memorial Hospital, Kanda-Izumicho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.

Heart and vessels

|September 12, 2023

概括

-葡萄糖携带载体-2 抑制剂 (SGLT2is),如达帕格利弗洛辛,可能会降低心力衰竭患者的心室节律失常. 这项研究发现,在心力衰竭患者中,达帕格利弗洛辛在一年后显著降低了心室再极化异质性,减少了射出分数 (HFrEF).

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
电子生理学电子生理学

背景情况:

-葡萄糖携带载体-2 抑制剂 (SGLT2is) 在减少心室节律失常和心脏突发死亡方面的作用仍在争论中.
心室再极化异质性是心室心律失常的已知危险因素.
在心力衰竭患者中,SGLT2is对心室再极化的影响需要进一步调查.

研究的目的:

为了前性地评估达帕格利弗洛辛对HFrEF患者心室再极化参数的影响.
评估QT间隔的变化,正确的QT间隔 (QTc),QT分散 (QTD),正确的QTD (QTcD),T峰到T末端 (TpTe),以及它们在一年中的比率.

主要方法:

一项前性研究涉及31名HFrEF患者的鼻节律新启动的达帕格利弗洛10毫克/天.
电心图参数包括QT间隔,QTc,QTD,QTcD,TpTe,TpTe/QT比率和TpTe/QTc比率在基线和治疗一年后进行测量.
进行统计分析以确定这些参数的显著变化.

主要成果:

一年后,QT间隔 (427.6 ± 52.6 ms与415.4 ± 35.1 ms相比; p=0.047),QTc间隔 (437.1 ± 37.3 ms与425.6 ± 22.7 ms相比; p=0.019),QTD (54.1 ± 11.8 ms与47.6 ± 14.7 ms相比; p=0.003),QTcD (56.0 ± 11.2 ms与49.4 ± 12.3 ms相比; p=0.004) 和TpTe (98.0 ± 15.6 ms与85.5 ± 20.9 ms相比; p=0.018) 显著减少.
TpTe/QTc比率也显著下降 (0.225 ± 0.035对比0.202 ± 0.051;p=0.044) 的时间.
在TpTe/QT比率 (0.231±0.040对比0.208±0.054;p=0.052) 中没有发现显著变化.

结论:

在HFrEF患者中,用达帕格利弗洛辛治疗一年显著减少了QT间隔,QT分散和TpTe.
这些发现表明,达帕格利弗洛辛可能通过降低心室再极化异质性来产生有益作用.
这种减少异质性可能有助于抑制这种患者群体的心室失常.

关键词:

心力衰竭与减少的喷射分数心力衰竭.在 QT 分散的过程中,-葡萄糖共运输体-2 抑制剂突然的心脏病死亡.腹腔室再极化是什么意思

更多相关视频

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

相关概念视频

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...